Last reviewed · How we verify
NCT04322292
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
Completed
Phase 1
Last updated 11 February 2026
What this trial tests
Phase 1 trial testing C-CAR088 in Multiple Myeloma in 9 participants. Completed in 22 September 2022.
Timeline
12 September 2019
Primary endpoint
22 September 2022
22 September 2022
22 September 2022
Quick facts
| Lead sponsor | Institute of Hematology & Blood Diseases Hospital, China |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 9 |
| Start date | 12 September 2019 |
| Primary completion | 22 September 2022 |
| Estimated completion | 22 September 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- C-CAR088 — full drug profile →
Conditions studied
- Multiple Myeloma — all drugs for Multiple Myeloma →
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Who can join
Adults 18 to 75, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-center, non-randomized and dose-escalation study to evaluate the safety and efficacy of C-CAR088 in relapsed or refractory multiple myeloma patient.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
CAR T-cell therapy in multiple myeloma: more room for improvement.
Teoh PJ, Chng WJ. · · 2021 · cited 123× · PMID 33927192 · DOI 10.1038/s41408-021-00469-5 -
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Kegyes D, Constantinescu C, Vrancken L, Rasche L, et al · · 2022 · cited 53× · PMID 35672793 · DOI 10.1186/s13045-022-01296-2 -
Targeting the Microenvironment for Treating Multiple Myeloma.
Neumeister P, Schulz E, Pansy K, Szmyra M, et al · · 2022 · cited 33× · PMID 35886976 · DOI 10.3390/ijms23147627 -
CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond.
Mishra AK, Gupta A, Dagar G, Das D, et al · · 2023 · cited 29× · PMID 38006053 · DOI 10.3390/vaccines11111721 -
Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma.
Qu X, An G, Sui W, Wang T, et al · · 2022 · cited 26× · PMID 36100310 · DOI 10.1136/jitc-2022-005145 -
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond.
Su CT, Ye JC. · · 2021 · cited 21× · PMID 34301270 · DOI 10.1186/s13045-021-01109-y -
Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment.
Ho M, Xiao A, Yi D, Zanwar S, et al · · 2022 · cited 20× · PMID 36421358 · DOI 10.3390/curroncol29110705 -
Chimeric antigen receptor T-cell therapy for multiple myeloma.
Wang Z, Chen C, Wang L, Jia Y, et al · · 2022 · cited 12× · PMID 36618390 · DOI 10.3389/fimmu.2022.1050522
Verify or expand the search:
- PubMed search for NCT04322292
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of C-CAR088
Trials testing the same drug.
- NCT05632380 — ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM) · Phase 1, PHASE2 · recruiting
- NCT03751293 — A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma · Phase 1 · unknown
Other recruiting trials for Multiple Myeloma
Currently open trials in the same condition.
- NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
- NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
- NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting
Other Institute of Hematology & Blood Diseases Hospital, China trials
Trials by the same sponsor.
- NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
- NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
- NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
- NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
- NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04322292 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
- Last refreshed: 11 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04322292.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing